ClinicalTrials.gg
CompletedNCT02068235Updated May 21, 2015

Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects

A Phase 1 interventional study of Ponesimod 5mg i.v. and Ponesimod i.v. in Healthy, sponsored by Actelion. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study consists of a single-dose pilot phase and a randomized, two-way crossover, single-dose main phase.The aim of this study is to evaluate the absolute bioavailability of the oral formulation (tablet) of ponesimod compared to an intravenous (i.v.) ponesimod formulation. Three subjects will be included in the pilot phase and 12 subjects in the main crossover phase.

02

Conditions studied

  • Healthy

Keywords

  • Ponesimod
  • Bioavailability
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in the local language prior to any study-mandated procedure.
  • ≥ 18 and ≤ 28 kg/m\^2 at screening.
  • No findings on the physical examination at screening.
  • Systolic blood pressure (SBP) 100-145 mmHg and diastolic blood pressure (DBP) 50-90 mmHg, measured on the dominant arm, after 5 min in the supine position at screening and Day -1 of pilot phase/ first treatment period in main phase.
  • 12-lead without clinically relevant abnormalities at screening and Day -1 pilot phase / first treatment period in main phase.
  • Negative results from urine drug screen at screening and Day -1 pilot phase / first treatment period in main phase.
  • Hematology and clinical chemistry variables not deviating from the normal range to a clinically relevant extent at screening.
  • Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Known allergic reactions or to the active compound or any of the drug formulation(s).
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to locate, access, or puncture or veins with a tendency to rupture during or after puncture).
  • Heart rate \< 50 or > 95 beats per minute (bpm) at screening or Day -1 of pilot phase / first treatment period in main phase on 12-lead measured after 5 min in the supine position.
  • PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) > 200 ms at screening and Day -1 of pilot phase / first treatment period in main phase.
  • Subjects with personal or family history of long (time interval from beginning of the Q wave until end of the T wave) syndrome or hypokalemia.
  • Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Previous exposure to the study medication within 3 months prior to screening.
  • Any treatment within 6 weeks or 5 half-lives of the drug, whichever is longer, before study drug administration.
  • Treatment with another drug within 3 months or 10 half-lives of the drug, whichever is longer, prior to screening or participation in more than 4 investigational drug studies within 1 year prior to screening.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Excessive caffeine consumption, defined as ≥ 800 mg (7 cups of coffee or 14 cups of tea) per day at screening.
  • Smoking within the last 3 months prior to screening and inability to refrain from smoking during the course of the study.
  • Treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines) within 2 weeks prior to screening.
  • Loss of 250 mL or more of blood within 3 months prior to screening.
  • Lymphopenia (\< 1000 cells/μL) at screening or Day -1 of pilot phase / first treatment period in main phase.
  • Viral, fungal (with exception of onychomycosis and dermatomycosis), bacterial, or protozoal infection within 4 weeks before the first study drug administration.
  • Positive results from the hepatitis serology, except for vaccinated subjects or subjects with past but resolved hepatitis, at screening.
  • Positive results from the (HIV) serology at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Legal incapacity or limited legal capacity at screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Pilot Phase

    Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).

    Drug: Ponesimod 5mg i.v.

  • Experimental
    Treatment A/Treatment B

    Subjects will receive Treatment A followed by Treatment B. Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning. Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning. There will be a washout period between doses of 12-15 days.

    Drug: Ponesimod i.v. · Drug: Ponesimod 10 mg tablet

  • Experimental
    Treatment B/Treatment A

    Subjects will receive Treatment B followed by Treatment A. Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning. Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning. There will be a washout period between doses of 12-15 days.

    Drug: Ponesimod i.v. · Drug: Ponesimod 10 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC(0-144h)) of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. AUC(0-144) will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification.

    Time frame: 7 Days

  2. Area under the plasma concentration-time curve (AUC(0-infinity)) of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. AUC(0-infinity) will be calculated by combining AUC(0-144) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.

    Time frame: 7 Days

  3. Maximum plasma concentration (Cmax) of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. Cmax will be calculated on the basis of the blood sampling time points.

    Time frame: 7 Days

  4. Plasma half life (t1/2) of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. t1/2 will be calculated on the basis of the blood sampling time points.

    Time frame: 7 Days

  5. Time to maximum plasma concentration (tmax) after oral administration of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. tmax will be calculated on the basis of the blood sampling time points.

    Time frame: 7 Days

  6. Total body clearance (CL) after intravenous administration of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. CL Total body clearance will be calculated as follows: CL = Dose / AUC(0-infinity).

    Time frame: 7 Days

  7. Volume of distribution (Vss) after intravenous administration of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. Vss will be estimated by CL \[(AUMC/AUC) - (infusion time/2)\], where AUMC is the area under the first moment curve.

    Time frame: 7 Days

  8. Absolute bioavailability (F) of after oral administration of ponesimod

    Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ponesimod, and at various time points up to 7 days after dosing. F will be calculated using the geometric means (as derived by the mixed effect model) of AUC(0-infinity).

    Time frame: 7 Days

Secondary outcomes

  1. Change from baseline up to Day 7 in systolic blood pressure

    Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm = writing arm). Measurements will be recorded in the supine position after the subject has rested for a 5-minute period.

    Time frame: 7 Days

  2. Change from baseline up to Day 7 in diastolic blood pressure

    Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm = writing arm). Measurements will be recorded in the supine position after the subject has rested for a 5-minute period.

    Time frame: 7 Days

  3. Change from baseline up to Day 7 in pulse rate

    Blood pressure (systolic and diastolic) and pulse rate will be measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm = writing arm). Measurements will be recorded in the supine position after the subject has rested for a 5-minute period.

    Time frame: 7 Days

  4. Change from baseline up to Day 7 in heart rate

    Heart rate will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting.

    Time frame: 7 Days

  5. Change from baseline up to Day 7 in PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex)

    PR interval will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting.

    Time frame: 7 Days

  6. Change from baseline up to Day 7 in QRS duration (time interval from the beginning of the Q wave to the end of the S wave)

    QRS duration will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting.

    Time frame: 7 Days

  7. Change from baseline up to Day 7 in QT interval (time interval from beginning of the Q wave until end of the T wave)

    QT interval will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting.

    Time frame: 7 Days

  8. Change from baseline up to Day 7 in QT interval according to Bazett's correction (QTcB)

    QTcB interval will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting. The QTcB interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Bazett's formula (QTcB = QT/RR\^0.5 where RR is 60/heart rate)

    Time frame: 7 Days

  9. Change from baseline up to Day 7 in QT interval according to Fridericia's correction (QTcF)

    QTcF interval will be determined from standard 12-lead electrocardiographs (ECGs) recorded in the supine position, after a 5-minute period of resting.The QTcF interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Fridericia's formula (QTcB = QT/RR\^0.33 where RR is 60/heart rate)

    Time frame: 7 Days

  10. Frequency of treatment-emergent ECG abnormalities from up to Day 7

    Treatment-emergent abnormalities will be determined from standard 12-lead ECGs recorded in the supine position, after a 5-minute period of resting. Treatment-emergent ECG abnormalities are any ECG abnormalities that occur up to 144 hours after each study drug administration.

    Time frame: 7 Days

07

Study locations

1 site
  • Simbec Research Limited
    Merthyr Tydfil, CF48 4DR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2014
First posted
Feb 21, 2014
Start
Aug 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02068235
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Feb 21, 2014
Start date
Aug 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
May 21, 2015

Study contacts

Daniela Baldoni, PharmD, PhD
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion